Female cancer survivors more likely to report cost-related non-adherence
the ONA take:
Significant gender differences in cost-related medication non-adherence (CRN) were found among cancer survivors after adjusting for differences in sociodemographic, health status, and insurance coverage, a new study published online ahead of print in the Journal of Cancer Survivorship.
Because it has been reported that cancer survivors delay or avoid necessary care due to costs, researchers sought to determine the prevalence of CRN by gender and other factors among cancer survivors.
For the study, researchers from the University of South Carolina Arnold School of Public Health, in Columbia, analyzed data from 15,159 cancer survivors. Of those, 7.4% of male and 12.5% of female survivors reported CRN.
Results showed that female cancer survivors were 27% more likely than males to report CRN. Researchers found that a higher number of comorbidities and activity limitations were associated with higher CRN rates for both males and females.
“Given the rapid increase in prescription drug costs, it is important to monitor closely the CRN in high-risk subgroups,” the authors conclude.
Significant gender differences in cost-related medication non-adherence were found among cancer survivors.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|